Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Oncolytics Biotech ( (ONCY) ).
Oncolytics Biotech announced promising clinical and translational findings for pelareorep in treating KRAS-mutant metastatic colorectal cancer, a challenging subgroup. The data showed a 33% objective response rate, significantly higher than historical rates, and indicated enhanced T-cell activity, supporting pelareorep’s potential as a transformative treatment option. The company plans to advance pelareorep into a controlled study to confirm its efficacy and establish a new treatment paradigm, reflecting its strategic focus on this multi-billion dollar market.
The most recent analyst rating on (ONCY) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. The company is engaged in the biotechnology industry with a market focus on gastrointestinal tumors, particularly colorectal cancer.
Average Trading Volume: 865,204
Technical Sentiment Signal: Strong Sell
Current Market Cap: $106.9M
Learn more about ONCY stock on TipRanks’ Stock Analysis page.